



**THE FOUNDATION
FOR SECURE
MARKETS®**

#59702

Date: September 03, 2026

Subject: Apogee Therapeutics, Inc. - Cash Settlement/Acceleration of Expirations
Option Symbols: APGE/2APGE
Date: 09/03/2026

On August 11, 2026, Shareholders of Apogee Therapeutics, Inc. (APGE) voted concerning the proposed merger with a wholly-owned subsidiary of Andor LLC, which is a wholly-owned subsidiary of AbbVie Inc. The merger was approved and subsequently consummated before the open on September 3, 2026. As a result, each existing APGE Common Share will be converted into the right to receive \$135.11 net cash per share.

Contract Adjustment

Date: September 3, 2026

New Deliverable
Per Contract: \$13,511.00 Cash (\$135.11 x 100)

Settlement in APGE/2APGE options will take place through OCC's cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable.

Acceleration of Expirations

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an acceleration of the expiration dates for outstanding option series. (See OCC Information Memo 23707) Additionally, the exercise by exception (ex by ex) threshold for expiring series will be \$.01 in all account types.

All series of Apogee Therapeutics, Inc. options whose expiration dates are after 09-18-2026 will have their expiration dates advanced to 09-18-2026. Expiration dates occurring before 09-18-2026 (e.g., Flex options) will remain unchanged.

All Apogee Therapeutics, Inc. options will utilize a \$.01 exercise threshold.

Option Symbols: APGE/2APGE
Existing Expiration: All months
New expiration date: 09-18-2026

Existing American-style Apogee Therapeutics, Inc. options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue to settle in one business day.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and futures and the nature of any adjustment is made by OCC pursuant to Chapter 28 (XXVIII) of OCC's Rules. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.